Cargando…

Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review

Cystic fibrosis (CF) is a genetic disease that causes absence or dysfunction of a protein named transmembrane conductance regulatory protein (CFTR) that works as an anion channel. As a result, the secretions of the organs where CFTR is expressed are very viscous, so their functionality is altered. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Girón Moreno, Rosa María, García-Clemente, Marta, Diab-Cáceres, Layla, Martínez-Vergara, Adrián, Martínez-García, Miguel Ángel, Gómez-Punter, Rosa Mar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144952/
https://www.ncbi.nlm.nih.gov/pubmed/33922413
http://dx.doi.org/10.3390/antibiotics10050486
_version_ 1783697066681171968
author Girón Moreno, Rosa María
García-Clemente, Marta
Diab-Cáceres, Layla
Martínez-Vergara, Adrián
Martínez-García, Miguel Ángel
Gómez-Punter, Rosa Mar
author_facet Girón Moreno, Rosa María
García-Clemente, Marta
Diab-Cáceres, Layla
Martínez-Vergara, Adrián
Martínez-García, Miguel Ángel
Gómez-Punter, Rosa Mar
author_sort Girón Moreno, Rosa María
collection PubMed
description Cystic fibrosis (CF) is a genetic disease that causes absence or dysfunction of a protein named transmembrane conductance regulatory protein (CFTR) that works as an anion channel. As a result, the secretions of the organs where CFTR is expressed are very viscous, so their functionality is altered. The main cause of morbidity is due to the involvement of the respiratory system as a result of recurrent respiratory infections by different pathogens. In recent decades, survival has been increasing, rising by around age 50. This is due to the monitoring of patients in multidisciplinary units, early diagnosis with neonatal screening, and advances in treatments. In this chapter, we will approach the different therapies used in CF for the treatment of symptoms, obstruction, inflammation, and infection. Moreover, we will discuss specific and personalized treatments to correct the defective gene and repair the altered protein CFTR. The obstacle for personalized CF treatment is to predict the drug response of patients due to genetic complexity and heterogeneity of uncommon mutations.
format Online
Article
Text
id pubmed-8144952
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81449522021-05-26 Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review Girón Moreno, Rosa María García-Clemente, Marta Diab-Cáceres, Layla Martínez-Vergara, Adrián Martínez-García, Miguel Ángel Gómez-Punter, Rosa Mar Antibiotics (Basel) Review Cystic fibrosis (CF) is a genetic disease that causes absence or dysfunction of a protein named transmembrane conductance regulatory protein (CFTR) that works as an anion channel. As a result, the secretions of the organs where CFTR is expressed are very viscous, so their functionality is altered. The main cause of morbidity is due to the involvement of the respiratory system as a result of recurrent respiratory infections by different pathogens. In recent decades, survival has been increasing, rising by around age 50. This is due to the monitoring of patients in multidisciplinary units, early diagnosis with neonatal screening, and advances in treatments. In this chapter, we will approach the different therapies used in CF for the treatment of symptoms, obstruction, inflammation, and infection. Moreover, we will discuss specific and personalized treatments to correct the defective gene and repair the altered protein CFTR. The obstacle for personalized CF treatment is to predict the drug response of patients due to genetic complexity and heterogeneity of uncommon mutations. MDPI 2021-04-23 /pmc/articles/PMC8144952/ /pubmed/33922413 http://dx.doi.org/10.3390/antibiotics10050486 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Girón Moreno, Rosa María
García-Clemente, Marta
Diab-Cáceres, Layla
Martínez-Vergara, Adrián
Martínez-García, Miguel Ángel
Gómez-Punter, Rosa Mar
Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review
title Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review
title_full Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review
title_fullStr Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review
title_full_unstemmed Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review
title_short Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review
title_sort treatment of pulmonary disease of cystic fibrosis: a comprehensive review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144952/
https://www.ncbi.nlm.nih.gov/pubmed/33922413
http://dx.doi.org/10.3390/antibiotics10050486
work_keys_str_mv AT gironmorenorosamaria treatmentofpulmonarydiseaseofcysticfibrosisacomprehensivereview
AT garciaclementemarta treatmentofpulmonarydiseaseofcysticfibrosisacomprehensivereview
AT diabcacereslayla treatmentofpulmonarydiseaseofcysticfibrosisacomprehensivereview
AT martinezvergaraadrian treatmentofpulmonarydiseaseofcysticfibrosisacomprehensivereview
AT martinezgarciamiguelangel treatmentofpulmonarydiseaseofcysticfibrosisacomprehensivereview
AT gomezpunterrosamar treatmentofpulmonarydiseaseofcysticfibrosisacomprehensivereview